2017年中国临床肿瘤学会年会原发性肝癌研究进展解析

Research progresses of primary liver cancer from 2017 annual meeting of Chinese Society of Clinical Oncology

2017年9月26—30日在厦门举行的第20届全国临床肿瘤学大会暨2017年中国临床肿瘤学会（CSCO）年会呈现出原发性肝癌诊断与治疗的一系列进展：（1）我国原发性肝癌真实世界的初步分析结果发布。（2）新兴诊断技术和预测模型可评估肝细胞癌（HCC）患者术前肝纤维化程度及术后肝衰竭发生风险。（3）光动力诊断技术能够确保肝切除术切缘阴性前提下实现病灶组织学清除．并最大程度保留正常肝实质。（4）仑伐替尼有望成为继索拉非尼后治疗进展期HCC的一线分子靶向药物。（5）以细胞程序性死亡受体-1纳武单克隆抗体和Pembrolizumab为首的免疫治疗仍是HCC领域的热点。（6）东西方国家原发性肝癌手术安全性及疗效相近，部分东方国家晚期原发性肝癌患者也应积极行手术干预。（7）常规淋巴结清扫、对分期较晚的肿瘤积极行手术干预、保证切缘阴性率及复发后综合治疗有望提高肝内胆管细胞癌远期疗效。

In the twentieth session of the National Clinical Oneology Conference and 2017 annual meeting of Chinese Society of Clinical Oneology （CSCO）, many progre- ssions have been made in the diagnosis and treatment of primary liver cancer. （ 1 ） A preliminary report of the real world study of primary liver cancer in China was released. （2） Emerging diagnostic techniques and predictive models can detect preoperative liver cirrhosis and risk of postoperative liver failure in patients with hepatocellular carcinoma （ HCC ）. （ 3 ） Photodynamic diagnostic technology can ensure histological clearance with negative surgical margin and preserve as much liver parenchyma as possible. （4） Lenvatinib is expected to be the first-line targeted drug for the treatment of patients with unresectable HCC follow- ing sorafenib. （5） Immunotherapy with Nivolumab and Pembro- lizumab is still a hot topic in the field of HCC management. （6） Though a vast heterogeneity of patterns of liver resection for HCC exists between two large centers from the East and the West, their surgical safety and long-term efficacy are actually comparable. （ 7 ） Routine lymphadenectomy, active surgical intervention for patients with late-stage tumors, ensuring the negative margins of resection and comprehensive treatment of postoperative recurrence are expected to improve the long-term outcomes of intrahepatic cholangiocarcinoma （ICC）.